Deans' stroke musings: Stroke, tested a new drug that repairs the damage

Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Friday, July 7, 2023

Stroke, tested a new drug that repairs the damage

This came out a year ago, what did your doctors and hospital do to get human testing going? NOTHING LIKE USUAL? Then you don't have a functioning stroke doctor or hospital!

Stroke, tested a new drug that repairs the damage

July 29, 2022

The researchers found that the drug is able to repair the damage caused by a stroke through two mechanisms: on the one hand it creates new connections between neurons, on the other hand it stimulates the migration of new neurons, derived from stem cells, to the site in where the injury occurred.

Furthermore, the drug has also been shown to be effective when treatment is started seven days after the stroke, so very late, while most of the currently known therapies need to be administered within hours of the event.

“We are very excited about the data, which show a significant improvement in motor and sensory function, spatial learning and memory,” said Agnes Luo of the University of Cincinnati, one of the authors of the study.

“The only drug currently approved by the Food and Drug Administration (the US government body that deals with the regulation of food and pharmaceutical products) for the treatment of stroke does not repair the damage and must be administered within 4.5 hours,” Luo continues: “A product that repairs damage even a week after the onset of symptoms would change the paradigm for the treatment of stroke”.

Further studies will be needed to confirm the results and verify whether the drug is equally effective in human patients. The pharmaceutical company NervGen Pharma, which holds the exclusive rights to NVG-291, plans to begin clinical trials on humans soon to evaluate the drug also in relation to spinal cord injuries, Alzheimer’s disease and multiple sclerosis.